1. Pink Sheet
  2. >>R&D

Partnering Interest In Infectious Disease Space Showing Promise Beyond HCV Hotspot

Antiviral agents and vaccines for indications beyond the red-hot hepatitis C indication highlight the infectious diseases track at this year’s Therapeutic Area Partnerships conference.

Infectious diseases might be the second-most inviting therapeutic space for partnering early- and mid-stage assets, behind only oncology, asserts industry consultant Virginia Herndon. And that activity goes far beyond the well-publicized, lucrative deal-making that has occurred in recent years around hepatitis C companies and candidates, she says.

President of Herndon Company LLC, Herndon organized the infectious disease track for Elsevier Business Intelligence’s Windhover Therapeutic Area Partnerships conference...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Orphan Drug Trial Sponsors ‘Playing Catch-Up’ With Regulators – But Automation Can Help

 
• By Eliza Slawther

Clinical trial sponsors in the rare disease space face “big safety demands” from regulators, which can be challenging for those with limited resources. A CRO founder makes the case for “embedding automation” into the clinical trial process to keep pace with regulatory requirements.

Nipah Vaccine With ‘Pandemic Potential’ Wins EMA PRIME Designation

 
• By Neena Brizmohun

The developers of the ChAdOx1 NipahB vaccine will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.

Elegy For SACHRP: US HHS Research Protection Panel Tackled Tough Pediatric Trial Questions

 
• By Bridget Silverman

The termination of the HHS Secretary’s Committee on Human Research Protections closed an important forum for discussing pediatrics and pregnancy in clinical trial design, a former SACHRP chair said.